Subjective Visual Vertical Test Has Low Sensitivity for Identifying Meniere Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 2, 2024 -- The subjective visual vertical (SVV) test has relatively low sensitivity for diagnosing Meniere disease, according to a study published in the July and August issue of the Iranian Journal of Otorhinolaryngology.
Hadi Behzad, Ph.D., from the Shahid Beheshti University of Medical Science in Tehran, Iran, and colleagues conducted a study on 53 patients with confirmed unilateral Meniere disease and a control group to examine use of the SVV test in static and dynamic models as well as the electrocochleography (ECochG) test for diagnosing Meniere disease.
The researchers found that the optimal cutoff point obtained for the tilt toward the lesion was 2.1 degrees of deviation, which had sensitivity of 0.698 and specificity of 0.717. This was identified as the best condition for differentiating individuals with Meniere disease from the healthy control group, but the levels of sensitivity and specificity were considered relatively low for an auditory test and unreliable in terms of diagnosis.
"Based on the current findings, the SVV test has relatively low sensitivity for diagnosing Meniere's disease. Therefore, relying solely on its results to identify Meniere's disease is not recommended," the authors write. "Future studies should explore other avenues besides using ECochG and SVV tests together."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.